Tharimmune's Oral 'Under The Cheek' Candidate At Par With FDA-Approved Injectable With Potential For Chronic Liver Disease
Portfolio Pulse from Vandana Singh
Tharimmune Inc (NASDAQ:THAR) completed its Phase 1 clinical trial for TH104, a transmucosal buccal film for chronic liver disease, showing safety and tolerability comparable to FDA-approved nalmefene. The trial's full data is expected in Q2 2024. Last quarter, Tharimmune closed an $11 million public offering to extend its cash runway into early 2025 for TH104's clinical readouts. THAR shares rose 0.26% to $0.39.
February 20, 2024 | 9:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tharimmune Inc completed Phase 1 trials for TH104, showing comparable safety to FDA-approved nalmefene. Full trial data expected in Q2 2024. An $11 million public offering was closed last quarter, extending cash runway into early 2025.
The successful completion of Phase 1 trials for TH104, with safety and tolerability comparable to an FDA-approved treatment, is a positive development for Tharimmune. The anticipation of full trial data in Q2 2024 and the recent $11 million public offering to fund further development are likely to generate investor optimism, potentially leading to a short-term positive impact on THAR's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100